Reported 2 days ago
Vaxcyte, Inc. (NASDAQ:PCVX), a biotech company specializing in vaccine innovation, experienced a significant stock sell-off in Q1 2025 due to disappointing data from its VAX-24 infant trials and leadership changes at the FDA affecting vaccine development perceptions. Despite a challenging quarter where Vaxcyte's stock fell over 60% in value annually, analysts believe the company's solid cash position and vaccine pipeline, including the promising VAX-31, signal potential recovery in the long run.
Source: YAHOO